Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab

Severe cases of COVID-19 are being reported in patients with comorbidities and drug-induced immunosuppression. The risk seems to depend on the type of immunosuppressive agents used, and it is particularly high with rituximab because of its long-lasting effects. We report a 71-year-old man with COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Berktas, Bahadir M., Koyuncu, Adem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991362/
https://www.ncbi.nlm.nih.gov/pubmed/35213815
http://dx.doi.org/10.4269/ajtmh.21-1010
Descripción
Sumario:Severe cases of COVID-19 are being reported in patients with comorbidities and drug-induced immunosuppression. The risk seems to depend on the type of immunosuppressive agents used, and it is particularly high with rituximab because of its long-lasting effects. We report a 71-year-old man with COVID-19, mantle cell lymphoma, and rituximab-associated immunodeficiency. His COVID-19 clinical course was severe, unremitting, prolonged, and with frequent acute exacerbations requiring hospitalization. Viral shedding and failure to develop anti-severe acute respiratory syndrome coronavirus 2 antibodies continued for at least 6 months.

Ejemplares similares